BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-42. [PMID: 15747110 DOI: 10.1007/s00125-005-1682-x] [Cited by in Crossref: 428] [Cited by in F6Publishing: 374] [Article Influence: 26.8] [Reference Citation Analysis]
Number Citing Articles
1 Leite NC, Villela-Nogueira CA, Cardoso CR, Salles GF. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol. 2014;20:8377-8392. [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
2 Konopelska S, Kienitz T, Quinkler M. Downregulation of hepatic glucose-6-phosphatase-α in patients with hepatic steatosis. Obesity (Silver Spring) 2011;19:2322-6. [PMID: 21593806 DOI: 10.1038/oby.2011.118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Liebe R, Keitel-anselmino V. Genetisches Risiko bei metabolischer Fettlebererkrankung: Gemeinsame Risikofaktoren für Fettlebererkrankung, Diabetes und Hyperlipidämie. Diabetologe 2020;16:552-9. [DOI: 10.1007/s11428-020-00647-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kato K, Takamura T, Takeshita Y, Ryu Y, Misu H, Ota T, Tokuyama K, Nagasaka S, Matsuhisa M, Matsui O, Kaneko S. Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease. PLoS One 2014;9:e92170. [PMID: 24651470 DOI: 10.1371/journal.pone.0092170] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
5 Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, Papatheodoridis GV. The Severity of Histologic Liver Lesions Is Independent of Body Mass Index in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2013;47:280-6. [DOI: 10.1097/mcg.0b013e31826be328] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
6 Yoshitaka H, Hamaguchi M, Kojima T, Fukuda T, Ohbora A, Fukui M. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study. Medicine (Baltimore). 2017;96:e6712. [PMID: 28471965 DOI: 10.1097/md.0000000000006712] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 9.3] [Reference Citation Analysis]
7 Yki-Järvinen H, Luukkonen PK, Hodson L, Moore JB. Dietary carbohydrates and fats in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34257427 DOI: 10.1038/s41575-021-00472-y] [Reference Citation Analysis]
8 Stättermayer AF, Traussnigg S, Aigner E, Kienbacher C, Huber-schönauer U, Steindl-munda P, Stadlmayr A, Wrba F, Trauner M, Datz C, Ferenci P. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. Journal of Trace Elements in Medicine and Biology 2017;39:100-7. [DOI: 10.1016/j.jtemb.2016.08.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
9 Matafome P, Nunes E, Louro T, Amaral C, Crisóstomo J, Rodrigues L, Moedas AR, Monteiro P, Cipriano A, Seiça R. A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. Naunyn-Schmied Arch Pharmacol 2009;379:241-51. [DOI: 10.1007/s00210-008-0363-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
10 Li T, Feng R, Zhao C, Wang Y, Wang J, Liu S, Cao J, Wang H, Wang T, Guo Y, Lu Z. Dimethylarginine Dimethylaminohydrolase 1 Protects Against High-Fat Diet-Induced Hepatic Steatosis and Insulin Resistance in Mice. Antioxidants & Redox Signaling 2017;26:598-609. [DOI: 10.1089/ars.2016.6742] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
11 Meroni M, Longo M, Fracanzani AL, Dongiovanni P. MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine 2020;57:102866. [PMID: 32629394 DOI: 10.1016/j.ebiom.2020.102866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
12 Otten J, Mellberg C, Ryberg M, Sandberg S, Kullberg J, Lindahl B, Larsson C, Hauksson J, Olsson T. Strong and persistent effect on liver fat with a Paleolithic diet during a two-year intervention. Int J Obes (Lond). 2016;40:747-753. [PMID: 26786351 DOI: 10.1038/ijo.2016.4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
13 Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009;41:265-278. [PMID: 19353360 DOI: 10.1080/07853890802552437] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 6.4] [Reference Citation Analysis]
14 Wang XM, Zhang XJ, Ma L. Diagnostic performance of magnetic resonance technology in detecting steatosis or fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Medicine (Baltimore) 2018;97:e10605. [PMID: 29794735 DOI: 10.1097/MD.0000000000010605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
15 Choe YG, Jin W, Cho YK, Chung WG, Kim HJ, Jeon WK, Kim BI. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. J Gastroenterol Hepatol. 2013;28:678-683. [PMID: 23215811 DOI: 10.1111/jgh.12077] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
16 Morio R, Hyogo H, Hatooka M, Morio K, Kan H, Kobayashi T, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Masayasu Y, Chayama K. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease. J Gastroenterol. 2017;52:253-262. [PMID: 27351871 DOI: 10.1007/s00535-016-1236-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
17 Valtuena S, Numeroso F, Ardigo D, Pedrazzoni M, Franzini L, Piatti PM, Monti L, Zavaroni I. Relation-ship between leptin, insulin, body composition and liver steatosis in non-diabetic moderate drinkers with normal transaminase levels. Eur J Endocrinol. 2005;153:283-290. [PMID: 16061835 DOI: 10.1530/eje.1.01960] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
18 Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93:S74-S80. [PMID: 18987273 DOI: 10.1210/jc.2008-1399] [Cited by in Crossref: 176] [Cited by in F6Publishing: 151] [Article Influence: 14.7] [Reference Citation Analysis]
19 Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, Canavesi E, Fracanzani AL, Mozzi E, Roviaro G, Magni P, Fargion S. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol. 2012;12:111. [PMID: 22898488 DOI: 10.1186/1471-230x-12-111] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 5.1] [Reference Citation Analysis]
20 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
21 Chalermchai T, Hiransuthikul N, Tangkijvanich P, Pinyakorn S, Avihingsanon A, Ananworanich J. Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection. AIDS Res Ther 2013;10:21. [PMID: 23885958 DOI: 10.1186/1742-6405-10-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
22 Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473-480. [PMID: 15981216 DOI: 10.1002/hep.20781] [Cited by in Crossref: 405] [Cited by in F6Publishing: 365] [Article Influence: 25.3] [Reference Citation Analysis]
23 Harrison SA. New treatments for nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2006;8:21-29. [PMID: 16510031 DOI: 10.1007/s11894-006-0060-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
24 Parry SA, Hodson L. Influence of dietary macronutrients on liver fat accumulation and metabolism. J Investig Med 2017;65:1102-15. [PMID: 28947639 DOI: 10.1136/jim-2017-000524] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 13.8] [Reference Citation Analysis]
25 Parola M, Marra F. Adipokines and Redox Signaling: Impact on Fatty Liver Disease. Antioxidants & Redox Signaling 2011;15:461-83. [DOI: 10.1089/ars.2010.3848] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
26 Isokuortti E, Zhou Y, Peltonen M, Bugianesi E, Clement K, Bonnefont-Rousselot D, Lacorte JM, Gastaldelli A, Schuppan D, Schattenberg JM, Hakkarainen A, Lundbom N, Jousilahti P, Männistö S, Keinänen-Kiukaanniemi S, Saltevo J, Anstee QM, Yki-Järvinen H. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. Diabetologia 2017;60:1873-82. [PMID: 28660493 DOI: 10.1007/s00125-017-4340-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 11.8] [Reference Citation Analysis]
27 Ashworth WB, Davies NA, Bogle ID. A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD. PLoS Comput Biol 2016;12:e1005105. [PMID: 27632189 DOI: 10.1371/journal.pcbi.1005105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
28 Kumar R, Rastogi A, Sharma MK, Bhatia V, Garg H, Bihari C, Sarin SK. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J Endocrinol Metab. 2013;17:665-671. [PMID: 23961483 DOI: 10.4103/2230-8210.113758] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 7.4] [Reference Citation Analysis]
29 Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711-725.e6. [PMID: 22326434 DOI: 10.1053/j.gastro.2012.02.003] [Cited by in Crossref: 482] [Cited by in F6Publishing: 417] [Article Influence: 53.6] [Reference Citation Analysis]
30 Naran NH, Haagensen M, Crowther NJ. Steatosis in South African women: How much and why? PLoS One 2018;13:e0191388. [PMID: 29351564 DOI: 10.1371/journal.pone.0191388] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
31 Pinzani M. Pathophysiology of non-alcoholic steatohepatitis and basis for treatment. Dig Dis 2011;29:243-8. [PMID: 21734391 DOI: 10.1159/000323928] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
32 Ding X, Xu Y, Wang Y, Li X, Lu C, Su J, Ma Y, Chen Y, Yin Y, Zhang L, Wu Y, Jin Y, Zheng L, Xu S, Zhu X, Ma J, Yu L, Jiang J, Zhao N, Yan Q, Greenberg AS, Huang Q, Ren Q, Sun H, Gu M, Zhao L, Huang Y, Wu Y, Qian C, Peng Y. Nonalcoholic Fatty Liver Disease and Associated Metabolic Risks of Hypertension in Type 2 Diabetes: A Cross-Sectional Community-Based Study. Int J Endocrinol 2017;2017:5262560. [PMID: 28458689 DOI: 10.1155/2017/5262560] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
33 Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013;19:5219-5238. [PMID: 23394097 DOI: 10.2174/13816128113199990381] [Cited by in Crossref: 128] [Cited by in F6Publishing: 107] [Article Influence: 18.3] [Reference Citation Analysis]
34 Carneros D, López-Lluch G, Bustos M. Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E3472. [PMID: 33198247 DOI: 10.3390/nu12113472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
35 Bedi O, Aggarwal S, Trehanpati N, Ramakrishna G, Krishan P. Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2019;9:607-18. [PMID: 31695251 DOI: 10.1016/j.jceh.2018.10.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
36 Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, Klein S. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010;95:2727-35. [PMID: 20371660 DOI: 10.1210/jc.2009-2622] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 9.3] [Reference Citation Analysis]
37 Hussein MA, Fawzi M, Ibrahim A, Saif A. Thyroid dysfunction and insulin resistance in patients with nonalcoholic fatty liver disease. Egypt J Intern Med 2018;30:97-102. [DOI: 10.4103/ejim.ejim_3_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Pan W, Ciociola E, Saraf M, Tumurbaatar B, Tuvdendorj D, Prasad S, Chandalia M, Abate N. Metabolic consequences of ENPP1 overexpression in adipose tissue. Am J Physiol Endocrinol Metab 2011;301:E901-11. [PMID: 21810932 DOI: 10.1152/ajpendo.00087.2011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
39 Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, Milburn M. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism. 2011;60:404-413. [PMID: 20423748 DOI: 10.1016/j.metabol.2010.03.006] [Cited by in Crossref: 276] [Cited by in F6Publishing: 235] [Article Influence: 25.1] [Reference Citation Analysis]
40 Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, Park CY, Oh KW, Sung KC, Kim BI. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol. 2010;105:2389-2395. [PMID: 20628364 DOI: 10.1038/ajg.2010.275] [Cited by in Crossref: 68] [Cited by in F6Publishing: 50] [Article Influence: 6.2] [Reference Citation Analysis]
41 Roden M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2:335-348. [PMID: 16932311 DOI: 10.1038/ncpendmet0190] [Cited by in Crossref: 259] [Cited by in F6Publishing: 237] [Article Influence: 17.3] [Reference Citation Analysis]
42 Fraser A, Ebrahim S, Smith GD, Lawlor DA. A comparison of associations of alanine aminotransferase and gamma-glutamyltransferase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. Hepatology 2007;46:158-65. [PMID: 17596883 DOI: 10.1002/hep.21667] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
43 Männistö VT, Simonen M, Hyysalo J, Soininen P, Kangas AJ, Kaminska D, Matte AK, Venesmaa S, Käkelä P, Kärjä V, Arola J, Gylling H, Cederberg H, Kuusisto J, Laakso M, Yki-järvinen H, Ala-korpela M, Pihlajamäki J. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. Liver Int 2015;35:1853-61. [DOI: 10.1111/liv.12769] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
44 Simon TG, Corey KE, Chung RT, Giugliano R. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci 2016;61:3425-35. [DOI: 10.1007/s10620-016-4330-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
45 Ke F, Xue G, Jiang X, Li F, Lai X, Zhang M, Shen Y, Gao L. Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease. Cytokine 2020;134:155184. [PMID: 32645536 DOI: 10.1016/j.cyto.2020.155184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
46 Novo E, Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair 2008;1:5. [PMID: 19014652 DOI: 10.1186/1755-1536-1-5] [Cited by in Crossref: 246] [Cited by in F6Publishing: 197] [Article Influence: 18.9] [Reference Citation Analysis]
47 Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol. 2015;7:846-858. [PMID: 25937862 DOI: 10.4254/wjh.v7.i6.846] [Cited by in Crossref: 162] [Cited by in F6Publishing: 131] [Article Influence: 27.0] [Reference Citation Analysis]
48 Choi S, Choi Y, Choi Y, Kim S, Jang J, Park T. Piperine reverses high fat diet-induced hepatic steatosis and insulin resistance in mice. Food Chem. 2013;141:3627-3635. [PMID: 23993530 DOI: 10.1016/j.foodchem.2013.06.028] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 6.5] [Reference Citation Analysis]
49 Paulino TL, Rafael MN, Hix S, Shigueoka DC, Ajzen SA, Kochi C, Suano-Souza FI, da Silva R, Costa-Carvalho BT, Sarni ROS. Is age a risk factor for liver disease and metabolic alterations in ataxia Telangiectasia patients? Orphanet J Rare Dis 2017;12:136. [PMID: 28778179 DOI: 10.1186/s13023-017-0689-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
50 Lattuada G, Ragogna F, Perseghin G. Why Does NAFLD Predict Type 2 Diabetes? Curr Diab Rep 2011;11:167-72. [DOI: 10.1007/s11892-011-0190-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
51 Yoo T, Choi W, Hong JH, Lee JY, Kim JM, Shin IS, Yang SJ, Amminger P, Berk M, Yoon JS, Kim SW. Association Between Vitamin D Insufficiency and Metabolic Syndrome in Patients With Psychotic Disorders. Psychiatry Investig 2018;15:396-401. [PMID: 29486549 DOI: 10.30773/pi.2017.08.30] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Chiang C, Huang C, Chan W, Chen J, Leu H. The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clinical Biochemistry 2010;43:1399-404. [DOI: 10.1016/j.clinbiochem.2010.09.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
53 Mehrdoost S, Yaghmaei P, Jafary H, Ebrahim-Habibi A. The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease. Iran J Basic Med Sci 2021;24:451-9. [PMID: 34094026 DOI: 10.22038/ijbms.2021.52239.11822] [Reference Citation Analysis]
54 Kantarceken B, Cetinkaya A, Inanc Tolun F, Yerhan H, Citirik C, Buyukbese MA. Metabolic conditions of fatty liver in non-diabetic obese women. J Endocrinol Invest 2007;30:672-6. [DOI: 10.1007/bf03347448] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Song H, Zheng Z, Wu J, Lai J, Chu Q, Zheng X. White Pitaya (Hylocereus undatus) Juice Attenuates Insulin Resistance and Hepatic Steatosis in Diet-Induced Obese Mice. PLoS One 2016;11:e0149670. [PMID: 26914024 DOI: 10.1371/journal.pone.0149670] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
56 Lee GH, Phyo WW, Loo WM, Kwok R, Ahmed T, Shabbir A, So J, Koh CJ, Hartono JL, Muthiah M, Lim K, Tan PS, Lee YM, Lim SG, Dan YY. Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population. World J Hepatol 2020;12:1228-38. [PMID: 33442450 DOI: 10.4254/wjh.v12.i12.1228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Fujita T, Daimon M, Mizushiri S, Nishiya Y, Murakami H, Tanabe J, Matsuhashi Y, Yanagimachi M, Tokuda I, Sawada K, Ihara K. FIB-4 index is a marker for a subsequent decrease in insulin secretion in a non-diabetic Japanese population. Sci Rep 2020;10:15814. [PMID: 32978491 DOI: 10.1038/s41598-020-72894-8] [Reference Citation Analysis]
58 Brouwers B, Schrauwen-hinderling V, Jelenik T, Gemmink A, Havekes B, Bruls Y, Dahlmans D, Roden M, Hesselink M, Schrauwen P. Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. Clinical Science 2017;131:1905-17. [DOI: 10.1042/cs20170261] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
59 Kotronen A, Seppälä-Lindroos A, Vehkavaara S, Bergholm R, Frayn KN, Fielding BA, Yki-Järvinen H. Liver fat and lipid oxidation in humans. Liver Int 2009;29:1439-46. [PMID: 19602132 DOI: 10.1111/j.1478-3231.2009.02076.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]
60 Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14:1483-1496. [PMID: 30263000 DOI: 10.7150/ijbs.27173] [Cited by in Crossref: 268] [Cited by in F6Publishing: 193] [Article Influence: 89.3] [Reference Citation Analysis]
61 Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, Finch J, Gastaldelli A, Harrison S, Tio F, Cusi K. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012;55:1389-97. [PMID: 22183689 DOI: 10.1002/hep.25539] [Cited by in Crossref: 230] [Cited by in F6Publishing: 202] [Article Influence: 25.6] [Reference Citation Analysis]
62 Dongiovanni P, Rametta R, Meroni M, Valenti L. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target? Expert Rev Gastroenterol Hepatol 2016;10:229-42. [PMID: 26641143 DOI: 10.1586/17474124.2016.1110018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
63 Armstrong MJ, Hazlehurst JM, Hull D, Guo K, Borrows S, Yu J, Gough SC, Newsome PN, Tomlinson JW. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab. 2014;16:651-660. [PMID: 24962805 DOI: 10.1111/dom.12272] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
64 Fülöp P, Paragh G. Patomechanisms of hepatic steatosis. Orvosi Hetilap 2010;151:323-9. [DOI: 10.1556/oh.2010.28816] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Bugianesi E, Bizzarri C, Rosso C, Mosca A, Panera N, Veraldi S, Dotta A, Giannone G, Raponi M, Cappa M, Alisi A, Nobili V. Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. American Journal of Gastroenterology 2017;112:1277-86. [DOI: 10.1038/ajg.2017.140] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
66 Elizondo-Montemayor L, Ugalde-Casas PA, Lam-Franco L, Bustamante-Careaga H, Serrano-González M, Gutiérrez NG, Martínez U. Association of ALT and the metabolic syndrome among Mexican children. Obes Res Clin Pract 2014;8:e79-87. [PMID: 24548580 DOI: 10.1016/j.orcp.2012.08.191] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
67 Bettermann K, Hohensee T, Haybaeck J. Steatosis and steatohepatitis: complex disorders. Int J Mol Sci. 2014;15:9924-9944. [PMID: 24897026 DOI: 10.3390/ijms15069924] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
68 Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133:496-506. [PMID: 17681171 DOI: 10.1053/j.gastro.2007.04.068] [Cited by in Crossref: 350] [Cited by in F6Publishing: 313] [Article Influence: 25.0] [Reference Citation Analysis]
69 Chen QF, Zhou XD, Sun YJ, Fang DH, Zhao Q, Huang JH, Jin Y, Wu JS. Sex-influenced association of non-alcoholic fatty liver disease with colorectal adenomatous and hyperplastic polyps. World J Gastroenterol. 2017;23:5206-5215. [PMID: 28811715 DOI: 10.3748/wjg.v23.i28.5206] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
70 Mey JT, Erickson ML, Axelrod CL, King WT, Flask CA, McCullough AJ, Kirwan JP. β-Hydroxybutyrate is reduced in humans with obesity-related NAFLD and displays a dose-dependent effect on skeletal muscle mitochondrial respiration in vitro. Am J Physiol Endocrinol Metab 2020;319:E187-95. [PMID: 32396388 DOI: 10.1152/ajpendo.00058.2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
71 Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349-364. [PMID: 29740166 DOI: 10.1038/s41575-018-0009-6] [Cited by in Crossref: 197] [Cited by in F6Publishing: 163] [Article Influence: 98.5] [Reference Citation Analysis]
72 Wooten JS, Nick TN, Seija A, Poole KE, Stout KB. High-Fructose Intake Impairs the Hepatic Hypolipidemic Effects of a High-Fat Fish-Oil Diet in C57BL/6 Mice. J Clin Exp Hepatol 2016;6:265-74. [PMID: 28003715 DOI: 10.1016/j.jceh.2016.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
73 Dâmaso AR, do Prado WL, de Piano A, Tock L, Caranti DA, Lofrano MC, Carnier J, Cristofalo DJ, Lederman H, Tufik S, de Mello MT. Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. Dig Liver Dis 2008;40:132-9. [PMID: 18082476 DOI: 10.1016/j.dld.2007.09.009] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
74 Croci I, Byrne NM, Choquette S, Hills AP, Chachay VS, Clouston AD, O'Moore-Sullivan TM, Macdonald GA, Prins JB, Hickman IJ. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut. 2013;62:1625-1633. [PMID: 23077135 DOI: 10.1136/gutjnl-2012-302789] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
75 Melis M, Tang XH, Trasino SE, Patel VM, Stummer DJ, Jessurun J, Gudas LJ. Effects of AM80 compared to AC261066 in a high fat diet mouse model of liver disease. PLoS One. 2019;14:e0211071. [PMID: 30677086 DOI: 10.1371/journal.pone.0211071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
76 Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci. 2016;73:1969-1987. [PMID: 26894897 DOI: 10.1007/s00018-016-2161-x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 18.2] [Reference Citation Analysis]
77 Peng L, Wu S, Zhou N, Zhu S, Liu Q, Li X. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity.BMC Pediatr. 2021;21:122. [PMID: 33711964 DOI: 10.1186/s12887-021-02595-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Markova M, Pivovarova O, Hornemann S, Sucher S, Frahnow T, Wegner K, Machann J, Petzke KJ, Hierholzer J, Lichtinghagen R, Herder C, Carstensen-Kirberg M, Roden M, Rudovich N, Klaus S, Thomann R, Schneeweiss R, Rohn S, Pfeiffer AF. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes. Gastroenterology. 2017;152:571-585.e8. [PMID: 27765690 DOI: 10.1053/j.gastro.2016.10.007] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
79 Portillo P, Yavuz S, Bril F, Cusi K. Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2014;13:159-70. [DOI: 10.1007/s11901-014-0229-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
80 Kazankov K, Barrera F, Møller HJ, Rosso C, Bugianesi E, David E, Younes R, Esmaili S, Eslam M, McLeod D, Bibby BM, Vilstrup H, George J, Grønbaek H. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver Int 2016;36:1549-57. [PMID: 27102725 DOI: 10.1111/liv.13150] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 12.2] [Reference Citation Analysis]
81 Post A, Garcia E, van den Berg EH, Flores-Guerrero JL, Gruppen EG, Groothof D, Westenbrink BD, Connelly MA, Bakker SJL, Dullaart RPF. Nonalcoholic fatty liver disease, circulating ketone bodies and all-cause mortality in a general population-based cohort. Eur J Clin Invest 2021;:e13627. [PMID: 34120339 DOI: 10.1111/eci.13627] [Reference Citation Analysis]
82 Huang G, Wang D, Zeb I, Budoff MJ, Harman SM, Miller V, Brinton EA, El Khoudary SR, Manson JE, Sowers MR. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis. 2012;221:198-205. [PMID: 22209479 DOI: 10.1016/j.atherosclerosis.2011.12.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
83 Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, Ciociaro D, Abate ML, Gambino R, Cassader M, Bugianesi E, Gastaldelli A. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. Hepatology. 2018;67:145-158. [PMID: 28802074 DOI: 10.1002/hep.29465] [Cited by in Crossref: 116] [Cited by in F6Publishing: 100] [Article Influence: 29.0] [Reference Citation Analysis]
84 Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, Cusi K. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther. 2010;32:769-775. [PMID: 20662773 DOI: 10.1111/j.1365-2036.2010.04405.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
85 Gastaldelli A. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011;93 Suppl 1:S60-S65. [PMID: 21864753 DOI: 10.1016/s0168-8227(11)70015-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 33] [Article Influence: 7.1] [Reference Citation Analysis]
86 Nicolson GL. Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function. J Cell Biochem. 2007;100:1352-1369. [PMID: 17243117 DOI: 10.1002/jcb.21247] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
87 Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40:1367-1393. [PMID: 31098621 DOI: 10.1210/er.2019-00034] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 66.0] [Reference Citation Analysis]
88 Vanni E, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, Smedile A, Ferrannini E, Rizzetto M, Marchesini G, Gastaldelli A, Bugianesi E. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology. 2009;50:697-706. [PMID: 19582803 DOI: 10.1002/hep.23031] [Cited by in Crossref: 114] [Cited by in F6Publishing: 106] [Article Influence: 9.5] [Reference Citation Analysis]
89 Cernkovich ER, Deng J, Bond MC, Combs TP, Harp JB. Adipose-specific disruption of signal transducer and activator of transcription 3 increases body weight and adiposity. Endocrinology 2008;149:1581-90. [PMID: 18096662 DOI: 10.1210/en.2007-1148] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
90 Di Pino A, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev 2019;40:1447-67. [PMID: 31050706 DOI: 10.1210/er.2018-00141] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 51.0] [Reference Citation Analysis]
91 Ter Horst KW, Serlie MJ. Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease. Nutrients. 2017;9. [PMID: 28878197 DOI: 10.3390/nu9090981] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 19.8] [Reference Citation Analysis]
92 Saely CH, Vonbank A, Rein P, Woess M, Beer S, Aczel S, Jankovic V, Boehnel C, Risch L, Drexel H. Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. Clin Chim Acta 2008;397:82-6. [PMID: 18708042 DOI: 10.1016/j.cca.2008.07.024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
93 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
94 Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int 2015;2015:460190. [PMID: 26273621 DOI: 10.1155/2015/460190] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 13.0] [Reference Citation Analysis]
95 Lim HW, Bernstein DE. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. Clin Liver Dis 2018;22:39-57. [PMID: 29128060 DOI: 10.1016/j.cld.2017.08.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
96 Bulum T, Kolarić B, Duvnjak L, Duvnjak M. Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci 2011;56:3655-63. [PMID: 21735081 DOI: 10.1007/s10620-011-1807-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
97 Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 2013;5:928-948. [PMID: 23507795 DOI: 10.3390/nu5030928.] [Reference Citation Analysis]
98 Song M, Xia L, Liu Q, Sun M, Wang F, Yang C. Sarcopenia in Liver Disease: Current Evidence and Issues to Be sResolved. Adv Exp Med Biol 2018;1088:413-33. [PMID: 30390263 DOI: 10.1007/978-981-13-1435-3_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Bozkurt L, Göbl CS, Tura A, Chmelik M, Prikoszovich T, Kosi L, Wagner O, Roden M, Pacini G, Gastaldelli A. Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS One. 2012;7:e32710. [PMID: 22393439 DOI: 10.1371/journal.pone.0032710] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
100 Valenti L, Riso P, Mazzocchi A, Porrini M, Fargion S, Agostoni C. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2013;2013:145421. [PMID: 24282628 DOI: 10.1155/2013/145421] [Cited by in Crossref: 74] [Cited by in F6Publishing: 58] [Article Influence: 9.3] [Reference Citation Analysis]
101 Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, Hazen SL, Feldstein AE. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology. 2012;56:1291-1299. [PMID: 22505276 DOI: 10.1002/hep.25778] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 12.5] [Reference Citation Analysis]
102 Kacerovsky M, Roden M. Nichtalkoholische Fettleber: Definition und Entstehung. Diabetologe 2007;3:176-83. [DOI: 10.1007/s11428-007-0130-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
103 Coccia F, Testa M, Guarisco G, Di Cristofano C, Silecchia G, Leonetti F, Gastaldelli A, Capoccia D. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD. Nutr Metab Cardiovasc Dis 2020;30:106-13. [PMID: 31677889 DOI: 10.1016/j.numecd.2019.08.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
104 Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, So WY, Cheng AY, Tong PC, Chan FK. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1215-1222. [PMID: 17014580 DOI: 10.1111/j.1365-2036.2006.03112.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 5.3] [Reference Citation Analysis]
105 Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013;5:928-48. [PMID: 23507795 DOI: 10.3390/nu5030928] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 10.3] [Reference Citation Analysis]
106 Fabbrini E, deHaseth D, Deivanayagam S, Mohammed BS, Vitola BE, Klein S. Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content. Obesity (Silver Spring) 2009;17:25-9. [PMID: 18948971 DOI: 10.1038/oby.2008.494] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 5.0] [Reference Citation Analysis]
107 Mato JM, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol 2019;25:3009-20. [PMID: 31293337 DOI: 10.3748/wjg.v25.i24.3009] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
108 Amaro A, Fabbrini E, Kars M, Yue P, Schechtman K, Schonfeld G, Klein S. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology. 2010;139:149-153. [PMID: 20303351 DOI: 10.1053/j.gastro.2010.03.039] [Cited by in Crossref: 103] [Cited by in F6Publishing: 89] [Article Influence: 9.4] [Reference Citation Analysis]
109 Hodson L. Hepatic fatty acid synthesis and partitioning: the effect of metabolic and nutritional state. Proc Nutr Soc 2019;78:126-34. [PMID: 30457067 DOI: 10.1017/S0029665118002653] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
110 Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S. Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. Int J Environ Res Public Health 2019;16:E4334. [PMID: 31703268 DOI: 10.3390/ijerph16224334] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
111 Yoon HJ, Cha BS. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J Hepatol. 2014;6:800-811. [PMID: 25429318 DOI: 10.4254/wjh.v6.i11.800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 7.1] [Reference Citation Analysis]
112 Jensen VS, Hvid H, Damgaard J, Nygaard H, Ingvorsen C, Wulff EM, Lykkesfeldt J, Fledelius C. Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats. Diabetol Metab Syndr. 2018;10:4. [PMID: 29410708 DOI: 10.1186/s13098-018-0307-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
113 Díaz-Montaña JJ, Díaz-Díaz N, Gómez-Vela F. GFD-Net: A novel semantic similarity methodology for the analysis of gene networks. J Biomed Inform 2017;68:71-82. [PMID: 28274758 DOI: 10.1016/j.jbi.2017.02.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
114 Lin YC, Wu CC, Ni YH. New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. Front Pediatr 2020;8:603654. [PMID: 33363067 DOI: 10.3389/fped.2020.603654] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
115 Spreghini N, Cianfarani S, Spreghini MR, Brufani C, Morino GS, Inzaghi E, Convertino A, Fintini D, Manco M. Oral glucose effectiveness and metabolic risk in obese children and adolescents. Acta Diabetol 2019;56:955-62. [PMID: 30868315 DOI: 10.1007/s00592-019-01303-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
116 Shin SK, Cho HW, Song SE, Song DK. Catalase and nonalcoholic fatty liver disease. Pflugers Arch 2018;470:1721-37. [PMID: 30120555 DOI: 10.1007/s00424-018-2195-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
117 Fathi M, Alavinejad P, Haidari Z, Amani R. The Effect of Zinc Supplementation on Steatosis Severity and Liver Function Enzymes in Overweight/Obese Patients with Mild to Moderate Non-alcoholic Fatty Liver Following Calorie-Restricted Diet: a Double-Blind, Randomized Placebo-Controlled Trial. Biol Trace Elem Res 2020;197:394-404. [PMID: 32020523 DOI: 10.1007/s12011-019-02015-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Dhurandhar NV. Insulin sparing action of adenovirus 36 and its E4orf1 protein. J Diabetes Complications. 2013;27:191-199. [PMID: 23246247 DOI: 10.1016/j.jdiacomp.2012.09.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
119 Perseghin G, Bonfanti R, Magni S, Lattuada G, De Cobelli F, Canu T, Esposito A, Scifo P, Ntali G, Costantino F, Bosio L, Ragogna F, Del Maschio A, Chiumello G, Luzi L. Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am J Physiol Endocrinol Metab 2006;291:E697-703. [PMID: 16684857 DOI: 10.1152/ajpendo.00017.2006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 5.0] [Reference Citation Analysis]
120 Perseghin G, Lattuada G, De Cobelli F, Esposito A, Costantino F, Canu T, Scifo P, De Taddeo F, Maffi P, Secchi A, Del Maschio A, Luzi L. Reduced intrahepatic fat content is associated with increased whole-body lipid oxidation in patients with type 1 diabetes. Diabetologia 2005;48:2615-21. [PMID: 16261312 DOI: 10.1007/s00125-005-0014-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
121 Doganer YC, Rohrer JE, Aydogan U, Agerter DC, Cayci T, Barcin C. Atherosclerosis and Liver Function Tests in Coronary Angiography Patients. West Indian Med J 2015;64:333-7. [PMID: 26624583 DOI: 10.7727/wimj.2014.192] [Reference Citation Analysis]
122 Nam SY. Obesity-Related Digestive Diseases and Their Pathophysiology. Gut Liver 2017;11:323-34. [PMID: 27890867 DOI: 10.5009/gnl15557] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 10.3] [Reference Citation Analysis]
123 Haeusler RA, Hartil K, Vaitheesvaran B, Arrieta-Cruz I, Knight CM, Cook JR, Kammoun HL, Febbraio MA, Gutierrez-Juarez R, Kurland IJ, Accili D. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun 2014;5:5190. [PMID: 25307742 DOI: 10.1038/ncomms6190] [Cited by in Crossref: 111] [Cited by in F6Publishing: 94] [Article Influence: 15.9] [Reference Citation Analysis]
124 Jonscher KR, Bruce KD. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. Adv Exp Med Biol 2019;1134:33-58. [PMID: 30919331 DOI: 10.1007/978-3-030-12668-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Montesi L, Mazzotti A, Moscatiello S, Forlani G, Marchesini G. Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH. Hepatol Int 2013;7:814-22. [DOI: 10.1007/s12072-013-9451-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
126 Marchesini G, Mazzotti A. NAFLD incidence and remission: only a matter of weight gain and weight loss? J Hepatol 2015;62:15-7. [PMID: 25450705 DOI: 10.1016/j.jhep.2014.10.023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
127 Valenti L, Rametta R, Dongiovanni P, Motta BM, Canavesi E, Pelusi S, Pulixi EA, Fracanzani AL, Fargion S. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One 2012;7:e48804. [PMID: 23144979 DOI: 10.1371/journal.pone.0048804] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
128 Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235-240. [PMID: 16970951 DOI: 10.1016/j.atherosclerosis.2006.08.021] [Cited by in Crossref: 355] [Cited by in F6Publishing: 303] [Article Influence: 23.7] [Reference Citation Analysis]
129 Bogdanova K, Poczatkova H, Uherkova L, Riegrova D, Rypka M, Feher J, Marchesini G, Vesely J. Non-alcoholic fatty liver disease (NAFLD)--a novel common aspect of the metabolic syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006;150:101-4. [PMID: 16936910 DOI: 10.5507/bp.2006.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
130 Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012;56:1311-1318. [PMID: 22532269 DOI: 10.1002/hep.25805] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
131 Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14:72-81. [PMID: 18218340 DOI: 10.1016/j.molmed.2007.12.003] [Cited by in Crossref: 293] [Cited by in F6Publishing: 272] [Article Influence: 22.5] [Reference Citation Analysis]
132 van der Graaff D, Kwanten WJ, Francque SM. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. Med Hypotheses 2019;122:188-97. [PMID: 30593409 DOI: 10.1016/j.mehy.2018.11.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
133 Hanafi MY, Zaher ELM, El-Adely SEM, Sakr A, Ghobashi AHM, Hemly MH, Kazem AH, Kamel MA. The therapeutic effects of bee venom on some metabolic and antioxidant parameters associated with HFD-induced non-alcoholic fatty liver in rats. Exp Ther Med 2018;15:5091-9. [PMID: 29805535 DOI: 10.3892/etm.2018.6028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
134 Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl). 2009;87:679-695. [PMID: 19352614 DOI: 10.1007/s00109-009-0464-1] [Cited by in Crossref: 188] [Cited by in F6Publishing: 156] [Article Influence: 15.7] [Reference Citation Analysis]
135 Abbate M, Montemayor S, Mascaró CM, Casares M, Gómez C, Ugarriza L, Tejada S, Abete I, Zulet MÁ, Sureda A, Martínez JA, Tur JA. Albuminuria Is Associated with Hepatic Iron Load in Patients with Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome. J Clin Med 2021;10:3187. [PMID: 34300354 DOI: 10.3390/jcm10143187] [Reference Citation Analysis]
136 Tominaga K, Fujimoto E, Suzuki K, Hayashi M, Ichikawa M, Inaba Y. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med 2009;14:142-9. [PMID: 19568858 DOI: 10.1007/s12199-008-0074-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
137 Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36:1497-507. [PMID: 33217052 DOI: 10.1111/jgh.15353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
138 Kumar R, Mohan S. Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications. J Clin Transl Hepatol. 2017;5:216-223. [PMID: 28936403 DOI: 10.14218/jcth.2016.00068] [Cited by in Crossref: 17] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
139 Gaggini M, Carli F, Gastaldelli A. The color of fat and its central role in the development and progression of metabolic diseases. Horm Mol Biol Clin Investig 2017;31:/j/hmbci. [PMID: 28942436 DOI: 10.1515/hmbci-2017-0060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
140 Hashimoto Y, Hamaguchi M, Tanaka M, Obora A, Kojima T, Fukui M. Metabolically healthy obesity without fatty liver and risk of incident type 2 diabetes: A meta-analysis of prospective cohort studies. Obes Res Clin Pract. 2018;12:4-15. [PMID: 29307656 DOI: 10.1016/j.orcp.2017.12.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
141 Wu J, Yao XY, Shi RX, Liu SF, Wang XY. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health. 2018;15:77. [PMID: 29747678 DOI: 10.1186/s12978-018-0519-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 12.7] [Reference Citation Analysis]
142 Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease: REVIEW: PAEDIATRIC NON-ALCOHOLIC FATTY LIVER DISEASE. Alimentary Pharmacology & Therapeutics 2008;28:13-24. [DOI: 10.1111/j.1365-2036.2008.03703.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 6.8] [Reference Citation Analysis]
143 Arata M, Nakajima J, Nishimata S, Nagata T, Kawashima H. Nonalcoholic steatohepatitis and insulin resistance in children. World J Diabetes 2014;5:917-23. [PMID: 25512797 DOI: 10.4239/wjd.v5.i6.917] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
144 Clanton J, Subichin M. The Effects of Metabolic Surgery on Fatty Liver Disease and Nonalcoholic Steatohepatitis. Surg Clin North Am. 2016;96:703-715. [PMID: 27473796 DOI: 10.1016/j.suc.2016.03.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
145 Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology. 2006;44:466-471. [PMID: 16871575 DOI: 10.1002/hep.21248] [Cited by in Crossref: 116] [Cited by in F6Publishing: 99] [Article Influence: 7.7] [Reference Citation Analysis]
146 Mashhood A, Railkar R, Yokoo T, Levin Y, Clark L, Fox-bosetti S, Middleton MS, Riek J, Kauh E, Dardzinski BJ, Williams D, Sirlin C, Shire NJ. Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. J Magn Reson Imaging 2013;37:1359-70. [DOI: 10.1002/jmri.23928] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
147 Saponaro C, Gaggini M, Carli F, Gastaldelli A. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients 2015;7:9453-74. [PMID: 26580649 DOI: 10.3390/nu7115475] [Cited by in Crossref: 197] [Cited by in F6Publishing: 157] [Article Influence: 32.8] [Reference Citation Analysis]
148 Gastaldelli A, Natali A, Vettor R, Corradini SG. Insulin resistance, adipose depots and gut: Interactions and pathological implications. Digestive and Liver Disease 2010;42:310-9. [DOI: 10.1016/j.dld.2010.01.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
149 Liu S, Yuan J, Yue W, Bi Y, Shen X, Gao J, Xu X, Lu Z. GCN2 deficiency protects against high fat diet induced hepatic steatosis and insulin resistance in mice. Biochim Biophys Acta Mol Basis Dis 2018;1864:3257-67. [PMID: 30006154 DOI: 10.1016/j.bbadis.2018.07.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
150 Dallio M, Diano N, Masarone M, Gravina AG, Patanè V, Romeo M, Di Sarno R, Errico S, Nicolucci C, Abenavoli L, Scarpellini E, Boccuto L, Persico M, Loguercio C, Federico A. Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. Int J Environ Res Public Health 2019;16:E3134. [PMID: 31466361 DOI: 10.3390/ijerph16173134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
151 Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 2012;32:279-286. [PMID: 22098614 DOI: 10.1111/j.1478-3231.2011.02637.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
152 Mannucci E, Monami M, Rotella C. How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. Nutrition, Metabolism and Cardiovascular Diseases 2007;17:719-26. [DOI: 10.1016/j.numecd.2006.09.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
153 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014.00177] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 11.1] [Reference Citation Analysis]
154 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
155 Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinol Diabetes Metab 2020;3:e00163. [PMID: 32704576 DOI: 10.1002/edm2.163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
156 Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2019;16:145-59. [DOI: 10.1038/s41575-018-0082-x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 158] [Article Influence: 59.0] [Reference Citation Analysis]
157 Hodson L, Gunn PJ. The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state. Nat Rev Endocrinol 2019;15:689-700. [DOI: 10.1038/s41574-019-0256-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 20.0] [Reference Citation Analysis]
158 Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15:607. [PMID: 25894944 DOI: 10.1007/s11892-015-0607-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
159 Tallarico V, Recinella G, Magalotti D, Muscari A, Zoli M, Bianchi G. Prognostic value of non-alcoholic fatty liver disease in the elderly patients. Aging Clin Exp Res 2020;32:2657-65. [PMID: 32008226 DOI: 10.1007/s40520-020-01487-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
160 Ausk KJ, Boyko EJ, Ioannou GN. Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care 2010;33:1179-85. [PMID: 20200308 DOI: 10.2337/dc09-2110] [Cited by in Crossref: 71] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
161 Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, Heim MH, Beglinger C. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One 2014;9:e87488. [PMID: 24489924 DOI: 10.1371/journal.pone.0087488] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
162 Hui E, Xu A, Bo Yang H, Lam KS. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. J Diabetes Investig 2013;4:413-25. [PMID: 24843689 DOI: 10.1111/jdi.12093] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
163 Singh SP, Misra B, Kar SK, Panigrahi MK, Misra D, Bhuyan P, Pattnaik K, Meher C, Agrawal O, Rout N, Swain M. Nonalcoholic fatty liver disease (NAFLD) without insulin resistance: Is it different?Clin Res Hepatol Gastroenterol. 2015;39:482-488. [PMID: 25543522 DOI: 10.1016/j.clinre.2014.08.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
164 Alferink LJM, Trajanoska K, Erler NS, Schoufour JD, de Knegt RJ, Ikram MA, Janssen HLA, Franco OH, Metselaar HJ, Rivadeneira F, Darwish Murad S. Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution. J Bone Miner Res. 2019;34:1254-1263. [PMID: 31074909 DOI: 10.1002/jbmr.3713] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
165 Cortez-pinto H, Machado M. Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2014;2:217-31. [DOI: 10.1586/17474124.2.2.217] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
166 Perseghin G. Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. Diabetes Care 2009;32 Suppl 2:S164-7. [PMID: 19875545 DOI: 10.2337/dc09-S303] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
167 Tura A, Pacini G, Winhofer Y, Bozkurt L, Di Benedetto G, Morbiducci U, Roden M, Kautzky-Willer A. Non-esterified fatty acid dynamics during oral glucose tolerance test in women with former gestational diabetes. Diabet Med 2012;29:351-8. [PMID: 21988496 DOI: 10.1111/j.1464-5491.2011.03477.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
168 Fabbrini E, Magkos F. Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients 2015;7:4995-5019. [PMID: 26102213 DOI: 10.3390/nu7064995] [Cited by in Crossref: 90] [Cited by in F6Publishing: 71] [Article Influence: 15.0] [Reference Citation Analysis]
169 de Piano A, Prado WL, Caranti DA, Siqueira KO, Stella SG, Lofrano M, Tock L, Cristofalo DM, Lederman H, Tufik S, de Mello MT, Dâmaso AR. Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2007;44:446-52. [PMID: 17414142 DOI: 10.1097/MPG.0b013e31803815d9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
170 Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 2007;24:1-6. [PMID: 17227317 DOI: 10.1111/j.1464-5491.2007.02025.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 148] [Article Influence: 11.2] [Reference Citation Analysis]
171 Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni C. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Research and Clinical Practice 2009;84:84-91. [DOI: 10.1016/j.diabres.2008.11.039] [Cited by in Crossref: 110] [Cited by in F6Publishing: 90] [Article Influence: 9.2] [Reference Citation Analysis]
172 Sharma S, Stine JG, Verbeek T, Bezinover D. Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00601-7. [PMID: 34391652 DOI: 10.1053/j.jvca.2021.07.020] [Reference Citation Analysis]
173 Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism 2016;65:1026-37. [DOI: 10.1016/j.metabol.2015.08.018] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 11.6] [Reference Citation Analysis]
174 Capeau J. Insulin resistance and steatosis in humans. Diabetes & Metabolism 2008;34:649-57. [DOI: 10.1016/s1262-3636(08)74600-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
175 Brea Á, Mosquera D, Mostaza JM, Aranda JL, Argimón J, Sanclemente C, Mateo-gallego R, Almagro F, Plana N, Recarte C. Hipertrigliceridemia, esteatosis hepática y riesgo cardiovascular. Clínica e Investigación en Arteriosclerosis 2011;23:72-7. [DOI: 10.1016/j.arteri.2011.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
176 Akhtar DH, Iqbal U, Vazquez-Montesino LM, Dennis BB, Ahmed A. Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2019;7:362-370. [PMID: 31915606 DOI: 10.14218/jcth.2019.00028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
177 Dhurandhar EJ, Krishnapuram R, Hegde V, Dubuisson O, Tao R, Dong XC, Ye J, Dhurandhar NV. E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia. PLoS One. 2012;7:e47813. [PMID: 23110104 DOI: 10.1371/journal.pone.0047813] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
178 Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, Abate ML, Vilstrup H, Gastaldelli A, George J, Grønbæk H, Bugianesi E. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. Journal of Hepatology 2019;71:1012-21. [DOI: 10.1016/j.jhep.2019.06.031] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 26.0] [Reference Citation Analysis]
179 Lonardo A, Suzuki A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. J Clin Med 2020;9:E1278. [PMID: 32354182 DOI: 10.3390/jcm9051278] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 26.0] [Reference Citation Analysis]
180 Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:7356-7365. [PMID: 24966606 DOI: 10.3748/wjg.v20.i23.7356] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
181 Salamone F, Li Volti G, Titta L, Puzzo L, Barbagallo I, La Delia F, Zelber-Sagi S, Malaguarnera M, Pelicci PG, Giorgio M, Galvano F. Moro orange juice prevents fatty liver in mice. World J Gastroenterol 2012;18:3862-8. [PMID: 22876038 DOI: 10.3748/wjg.v18.i29.3862] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
182 Koska J, Ortega E, Bogardus C, Krakoff J, Bunt JC. The effect of insulin on net lipid oxidation predicts worsening of insulin resistance and development of type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2007;293:E264-9. [PMID: 17616607 DOI: 10.1152/ajpendo.00662.2006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
183 Carvalho JAM, Barengo NC, Tuomilehto J, Conceição RD, Santos RD. The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis. Annals of Medicine 2011;43:487-94. [DOI: 10.3109/07853890.2011.554428] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
184 Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology. 2009;50:1087-1093. [PMID: 19670459 DOI: 10.1002/hep.23116] [Cited by in Crossref: 169] [Cited by in F6Publishing: 148] [Article Influence: 14.1] [Reference Citation Analysis]
185 Papaetis GS. Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state. Arch Med Sci Atheroscler Dis 2021;6:e57-78. [PMID: 34027215 DOI: 10.5114/amsad.2021.105314] [Reference Citation Analysis]
186 Marchesini G, Marzocchi R. Metabolic Syndrome and NASH. Clin Liver Dis. 2007;11:105-117, ix. [PMID: 17544974 DOI: 10.1016/j.cld.2007.02.013] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 5.6] [Reference Citation Analysis]
187 Cunha GM, Guzman G, Correa De Mello LL, Trein B, Spina L, Bussade I, Marques Prata J, Sajoux I, Countinho W. Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients With Obesity. Front Endocrinol (Lausanne) 2020;11:607. [PMID: 33042004 DOI: 10.3389/fendo.2020.00607] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
188 Pi-Sunyer FX. How effective are lifestyle changes in the prevention of type 2 diabetes mellitus? Nutr Rev 2007;65:101-10. [PMID: 17425061 DOI: 10.1111/j.1753-4887.2007.tb00287.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
189 Cheng F, Han L, Xiao Y, Pan C, Li Y, Ge X, Zhang Y, Yan S, Wang M. d- chiro-Inositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance via PKCε-PI3K/AKT Pathway. J Agric Food Chem 2019;67:5957-67. [PMID: 31066268 DOI: 10.1021/acs.jafc.9b01253] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
190 Suh JB, Kim SM, Cho GJ, Choi KM. Serum AFBP levels are elevated in patients with nonalcoholic fatty liver disease. Scand J Gastroenterol 2014;49:979-85. [PMID: 24957697 DOI: 10.3109/00365521.2013.836754] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
191 Thomas JJ, Ren J. Obstructive sleep apnoea and cardiovascular complications: perception versus knowledge. Clin Exp Pharmacol Physiol 2012;39:995-1003. [PMID: 23082844 DOI: 10.1111/1440-1681.12024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
192 Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, He H, Liu X, Li Y, Yu C. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64:925-932. [PMID: 26639394 DOI: 10.1016/j.jhep.2015.11.022] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 12.3] [Reference Citation Analysis]
193 Abolfathi M, Mohd-Yusof BN, Hanipah ZN, Mohd Redzwan S, Yusof LM, Khosroshahi MZ. The effects of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med 2020;48:102273. [PMID: 31987257 DOI: 10.1016/j.ctim.2019.102273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
194 Caviglia GP, Rosso C, Armandi A, Gaggini M, Carli F, Abate ML, Olivero A, Ribaldone DG, Saracco GM, Gastaldelli A, Bugianesi E. Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. Int J Mol Sci 2020;21:E8838. [PMID: 33266488 DOI: 10.3390/ijms21228838] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
195 Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013;5:1544-60. [PMID: 23666091 DOI: 10.3390/nu5051544] [Cited by in Crossref: 406] [Cited by in F6Publishing: 337] [Article Influence: 50.8] [Reference Citation Analysis]
196 Valenti L, Mendoza RM, Rametta R, Maggioni M, Kitajewski C, Shawber CJ, Pajvani UB. Hepatic Notch Signalling Correlates with Insulin Resistance and Non-Alcoholic Fatty Liver Disease. Diabetes. 2013;62:4052-4062. [PMID: 23990360 DOI: 10.2337/db13-0769] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
197 Harjumäki R, Pridgeon CS, Ingelman-Sundberg M. CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. Int J Mol Sci 2021;22:8221. [PMID: 34360999 DOI: 10.3390/ijms22158221] [Reference Citation Analysis]
198 Chen Z, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16:203. [PMID: 29037210 DOI: 10.1186/s12944-017-0572-9] [Cited by in Crossref: 100] [Cited by in F6Publishing: 85] [Article Influence: 25.0] [Reference Citation Analysis]
199 Viljanen AP, Iozzo P, Borra R, Kankaanpää M, Karmi A, Lautamäki R, Järvisalo M, Parkkola R, Rönnemaa T, Guiducci L. Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metab. 2009;94:50-55. [PMID: 18957499 DOI: 10.1210/jc.2008-1689] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 6.6] [Reference Citation Analysis]
200 Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology. 2007;132:2191-2207. [PMID: 17498512 DOI: 10.1053/j.gastro.2007.03.055] [Cited by in Crossref: 217] [Cited by in F6Publishing: 197] [Article Influence: 15.5] [Reference Citation Analysis]
201 Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368:1-19. [PMID: 16480697 DOI: 10.1016/j.cca.2005.12.026] [Cited by in Crossref: 183] [Cited by in F6Publishing: 146] [Article Influence: 12.2] [Reference Citation Analysis]
202 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol. 2016;7:211-217. [PMID: 27190693 DOI: 10.3349/ymj.2016.57.4.885] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
203 Ota T. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Adv Exp Med Biol 2021;1261:223-9. [PMID: 33783745 DOI: 10.1007/978-981-15-7360-6_20] [Reference Citation Analysis]
204 Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679-689. [PMID: 20041406 DOI: 10.1002/hep.23280] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 917] [Article Influence: 97.8] [Reference Citation Analysis]
205 Ore A, Akinloye OA, Adeogun AI, Ugbaja RN, Morifi E, Makatini M, Moepya R, Mbhele T. Buchholzia coriacea seed (wonderful kolanut) alleviates insulin resistance, steatosis, inflammation and oxidative stress in high fat diet model of fatty liver disease. J Food Biochem 2021;:e13836. [PMID: 34184286 DOI: 10.1111/jfbc.13836] [Reference Citation Analysis]
206 Cheng F, Yun SJ, Cao JL, Chang MC, Meng JL, Liu JY, Cheng YF, Feng CP. Differential Gene Expression and Biological Analyses of Primary Hepatocytes Following D-Chiro-Inositol Supplement. Front Endocrinol (Lausanne) 2021;12:700049. [PMID: 34335474 DOI: 10.3389/fendo.2021.700049] [Reference Citation Analysis]
207 Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320-330. [PMID: 20207596 DOI: 10.1016/j.dld.2010.01.016] [Cited by in Crossref: 301] [Cited by in F6Publishing: 276] [Article Influence: 27.4] [Reference Citation Analysis]
208 Bedi O, Aggarwal S, Trehanpati N, Ramakrishna G, Grewal AS, Krishan P. In vitro targeted screening and molecular docking of stilbene, quinones, and flavonoid on 3T3-L1 pre-adipocytes for anti-adipogenic actions. Naunyn-Schmiedeberg's Arch Pharmacol 2020;393:2093-106. [DOI: 10.1007/s00210-020-01919-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
209 Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World J Gastroenterol. 2015;21:12989-12995. [PMID: 26675364 DOI: 10.3748/wjg.v21.i46.12989] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
210 Morelli M, Gaggini M, Daniele G, Marraccini P, Sicari R, Gastaldelli A. Ectopic fat: the true culprit linking obesity and cardiovascular disease? Thromb Haemost 2013;110:651-60. [PMID: 23884194 DOI: 10.1160/TH13-04-0285] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
211 Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol. 2016;22:4079-4090. [PMID: 27122660 DOI: 10.3748/wjg.v22.i16.4079] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
212 Ioannou GN. Implications of elevated serum alanine aminotransferase levels: think outside the liver. Gastroenterology. 2008;135:1851-1854. [PMID: 19007778 DOI: 10.1053/j.gastro.2008.11.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
213 Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) 2010;18:1510-5. [PMID: 20395947 DOI: 10.1038/oby.2010.90] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 5.8] [Reference Citation Analysis]
214 Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, Ragogna F, Canu T, Scifo P, Del Maschio A. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology. 2008;47:51-58. [PMID: 17955548 DOI: 10.1002/hep.21983] [Cited by in Crossref: 143] [Cited by in F6Publishing: 127] [Article Influence: 11.0] [Reference Citation Analysis]
215 Salamone F, Bugianesi E. Nonalcoholic fatty liver disease: the hepatic trigger of the metabolic syndrome. J Hepatol. 2010;53:1146-1147. [PMID: 20817302 DOI: 10.1016/j.jhep.2010.06.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
216 Sung KC, Lee MY, Lee JY, Lee SH, Kim YB, Song WJ, Huh JH, Park JS, Shin JH, Seo MH, Kim SH, Kim SH. Natural course of fatty liver in 36,195 South Korean adults. Sci Rep 2019;9:9062. [PMID: 31308382 DOI: 10.1038/s41598-019-44738-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
217 Grønbaek H, Thomsen KL, Rungby J, Schmitz O, Vilstrup H. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol. 2008;2:705-711. [PMID: 19072347 DOI: 10.1586/17474124.2.5.705] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
218 Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011;5:24-34. [PMID: 21660248 DOI: 10.2174/1874192401105010024] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
219 Utzschneider KM, Kahn SE. The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism 2006;91:4753-61. [DOI: 10.1210/jc.2006-0587] [Cited by in Crossref: 476] [Cited by in F6Publishing: 419] [Article Influence: 31.7] [Reference Citation Analysis]
220 Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013;19:6969-78. [PMID: 24222941 DOI: 10.3748/wjg.v19.i41.6969] [Cited by in CrossRef: 135] [Cited by in F6Publishing: 126] [Article Influence: 19.3] [Reference Citation Analysis]
221 Snel M, Jonker JT, Schoones J, Lamb H, de Roos A, Pijl H, Smit JW, Meinders AE, Jazet IM. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol. 2012;2012:983814. [PMID: 22675355 DOI: 10.1155/2012/983814] [Cited by in Crossref: 134] [Cited by in F6Publishing: 105] [Article Influence: 14.9] [Reference Citation Analysis]
222 Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011;43:167-71. [PMID: 21476786 DOI: 10.3109/07853890.2011.561363] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
223 Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, Balasubramanyam M. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem. 2010;43:815-821. [PMID: 20398645 DOI: 10.1016/j.clinbiochem.2010.04.003] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 6.1] [Reference Citation Analysis]
224 Hogg K, Wood C, McNeilly AS, Duncan WC. The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep. PLoS One 2011;6:e24877. [PMID: 21935484 DOI: 10.1371/journal.pone.0024877] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
225 Wang S, Kamat A, Pergola P, Swamy A, Tio F, Cusi K. Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo. Metabolism 2011;60:1090-9. [PMID: 21310443 DOI: 10.1016/j.metabol.2010.12.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
226 Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism. 2011;60:1278-1284. [PMID: 21411114 DOI: 10.1016/j.metabol.2011.01.011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
227 Green CJ, Parry SA, Gunn PJ, Ceresa CDL, Rosqvist F, Piché ME, Hodson L. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. Horm Mol Biol Clin Investig 2018;41:/j/hmbci. [PMID: 30098284 DOI: 10.1515/hmbci-2018-0038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
228 Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933-22966. [PMID: 24264040 DOI: 10.3390/ijms141122933] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
229 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
230 Perez M, Gonzáles L, Olarte R, Rodríguez NI, Tabares M, Salazar JP, Jaimes S, García RG, López-Jaramillo P. Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population. Prev Med. 2011;52:174-177. [PMID: 21147154 DOI: 10.1016/j.ypmed.2010.11.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
231 Sangouni AA, Ghavamzadeh S, Jamalzehi A. A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:2260-5. [DOI: 10.1016/j.dsx.2019.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
232 Jiang B, Chen Y, Zhou K, Zheng Y, Chen Y, Li Q, Zhu C, Xia F, Gu T, Guo Y, Lu Y. Comparison of Abdominal Obesity and Fatty Liver and Their Association with Insulin Resistance and Metabolic Syndrome in Chinese Adults. Obesity (Silver Spring) 2019;27:707-15. [PMID: 30942551 DOI: 10.1002/oby.22432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
233 Phey Ming Yeap, Lockman KA, Elton R, Boyd M, Hayes PC, Jaap AJ. Comparison of the effects of long-term pioglitazone and rosiglitazone therapy on liver enzymes in type 2 diabetes. Diabetes & Vascular Disease 2011;11:121-9. [DOI: 10.1177/1474651411402630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
234 Chen HJ, Ko CY, Xu JH, Huang YC, Wu JS, Shen SC. Alleviative Effect of Ruellia tuberosa L. on Insulin Resistance and Abnormal Lipid Accumulation in TNF-α-Treated FL83B Mouse Hepatocytes. Evid Based Complement Alternat Med 2021;2021:9967910. [PMID: 34257694 DOI: 10.1155/2021/9967910] [Reference Citation Analysis]
235 Valenti L, Bugianesi E, Pajvani U, Targher G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int 2016;36:1563-79. [DOI: 10.1111/liv.13185] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 17.0] [Reference Citation Analysis]
236 Zhang R, Cheng K, Xu S, Li S, Zhou Y, Zhou S, Kong R, Li L, Li J, Feng J, Wu L, Liu T, Xia Y, Lu J, Guo C, Zhou Y. Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Gastroenterol Res Pract 2017;2017:8491742. [PMID: 28133479 DOI: 10.1155/2017/8491742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
237 Chen G, Ni Y, Nagata N, Xu L, Ota T. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17:1379. [PMID: 27563875 DOI: 10.3390/ijms17091379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
238 Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennett C, Kalhan SC. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2011;23:382-388. [PMID: 21448070 DOI: 10.1097/MEG.0b013e328345c8c7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
239 Slyper AH, Rosenberg H, Kabra A, Huang WM, Blech B, Matsumura MM. Fatty liver disease, glucose tolerance and insulin resistance in obese adolescents. Pediatr Obes 2015;10:423-7. [PMID: 25522002 DOI: 10.1111/ijpo.279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
240 Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699-711. [PMID: 21292470 DOI: 10.1016/j.jnutbio.2010.10.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 109] [Article Influence: 11.3] [Reference Citation Analysis]
241 Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015;239:192-202. [PMID: 25617860 DOI: 10.1016/j.atherosclerosis.2015.01.001] [Cited by in Crossref: 175] [Cited by in F6Publishing: 144] [Article Influence: 29.2] [Reference Citation Analysis]
242 Manti S, Romano C, Chirico V, Filippelli M, Cuppari C, Loddo I, Salpietro C, Arrigo T. Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic “mal-programming”. Hepat Mon. 2014;14:e17641. [PMID: 24829591 DOI: 10.5812/hepatmon.17641] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
243 Ruscica M, Ferri N, Macchi C, Meroni M, Lanti C, Ricci C, Maggioni M, Fracanzani AL, Badiali S, Fargion S, Magni P, Valenti L, Dongiovanni P. Liver fat accumulation is associated with circulating PCSK9. Ann Med. 2016;48:384-391. [PMID: 27222915 DOI: 10.1080/07853890.2016.1188328] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 12.4] [Reference Citation Analysis]
244 Sao R, Aronow WS. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci 2018;14:1233-44. [PMID: 30393477 DOI: 10.5114/aoms.2017.68821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
245 Rattarasarn C. Physiological and pathophysiological regulation of regional adipose tissue in the development of insulin resistance and type 2 diabetes. Acta Physiol 2006;186:87-101. [DOI: 10.1111/j.1748-1716.2005.01521.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
246 Bozzetto L, Prinster A, Mancini M, Giacco R, De Natale C, Salvatore M, Riccardi G, Rivellese AA, Annuzzi G. Liver fat in obesity: role of type 2 diabetes mellitus and adipose tissue distribution. Eur J Clin Invest 2011;41:39-44. [PMID: 20825466 DOI: 10.1111/j.1365-2362.2010.02372.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
247 Lee S, Rivera-Vega M, Alsayed HM, Boesch C, Libman I. Metabolic inflexibility and insulin resistance in obese adolescents with non-alcoholic fatty liver disease. Pediatr Diabetes 2015;16:211-8. [PMID: 24754380 DOI: 10.1111/pedi.12141] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
248 Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: The metabolic movers. Journal of Gastroenterology and Hepatology 2010;25:672-90. [DOI: 10.1111/j.1440-1746.2010.06253.x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 11.3] [Reference Citation Analysis]
249 Perseghin G. Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis. Diabetes Care. 2011;34 Suppl 2:S367-S370. [PMID: 21525484 DOI: 10.2337/dc11-s249] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
250 Popov VB, Lim JK. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol. 2015;3:230-238. [PMID: 26623270 DOI: 10.14218/jcth.2015.00019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 4.2] [Reference Citation Analysis]
251 Iozzo P. Viewpoints on the way to the consensus session: where does insulin resistance start? The adipose tissue. Diabetes Care 2009;32 Suppl 2:S168-73. [PMID: 19875546 DOI: 10.2337/dc09-S304] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
252 Gunn PJ, Pramfalk C, Millar V, Cornfield T, Hutchinson M, Johnson EM, Nagarajan SR, Troncoso-Rey P, Mithen RF, Pinnick KE, Traka MH, Green CJ, Hodson L. Modifying nutritional substrates induces macrovesicular lipid droplet accumulation and metabolic alterations in a cellular model of hepatic steatosis. Physiol Rep 2020;8:e14482. [PMID: 32643289 DOI: 10.14814/phy2.14482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Gastaldelli A, Basta G. Ectopic fat and cardiovascular disease: what is the link? Nutr Metab Cardiovasc Dis. 2010;20:481-490. [PMID: 20659791 DOI: 10.1016/j.numecd.2010.05.005] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 8.6] [Reference Citation Analysis]
254 Willmes DM, Kurzbach A, Henke C, Schumann T, Zahn G, Heifetz A, Jordan J, Helfand SL, Birkenfeld AL. The longevity gene INDY ( I 'm N ot D ead Y et) in metabolic control: Potential as pharmacological target. Pharmacology & Therapeutics 2018;185:1-11. [DOI: 10.1016/j.pharmthera.2017.10.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
255 Matafome P, Louro T, Rodrigues L, Crisóstomo J, Nunes E, Amaral C, Monteiro P, Cipriano A, Seiça R. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 2011;27:54-62. [PMID: 21218508 DOI: 10.1002/dmrr.1157] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
256 Kanwar P, Kowdley KV. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clin Liver Dis. 2016;20:225-243. [PMID: 27063266 DOI: 10.1016/j.cld.2015.10.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 8.3] [Reference Citation Analysis]
257 Kusters YH, Schalkwijk CG, Houben AJ, Kooi ME, Lindeboom L, Op 't Roodt J, Joris PJ, Plat J, Mensink RP, Barrett EJ, Stehouwer CD. Independent tissue contributors to obesity-associated insulin resistance. JCI Insight 2017;2:89695. [PMID: 28679946 DOI: 10.1172/jci.insight.89695] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
258 Stadlmayr A, Aigner E, Steger B, Scharinger L, Lederer D, Mayr A, Strasser M, Brunner E, Heuberger A, Hohla F. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med. 2011;270:41-49. [PMID: 21414047 DOI: 10.1111/j.1365-2796.2011.02377.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 7.6] [Reference Citation Analysis]
259 Cao G, Yi T, Liu Q, Wang M, Tang S. Alcohol consumption and risk of fatty liver disease: a meta-analysis. PeerJ 2016;4:e2633. [PMID: 27812428 DOI: 10.7717/peerj.2633] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
260 Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57:1378-1383. [PMID: 23213066 DOI: 10.1002/hep.26183] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 12.4] [Reference Citation Analysis]
261 Chao HW, Chao SW, Lin H, Ku HC, Cheng CF. Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E298. [PMID: 30642126 DOI: 10.3390/ijms20020298] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
262 Kheirandish-gozal L, Sans Capdevila O, Kheirandish E, Gozal D. Elevated Serum Aminotransferase Levels in Children at Risk for Obstructive Sleep Apnea. Chest 2008;133:92-9. [DOI: 10.1378/chest.07-0773] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 5.3] [Reference Citation Analysis]
263 Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis. 2007;17:63-70. [PMID: 17164082 DOI: 10.1016/j.numecd.2006.08.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
264 Mouralidarane A, Lin CI, Suleyman N, Soeda J, Oben JA. Practical management of the increasing burden of non-alcoholic fatty liver disease. Frontline Gastroenterol 2010;1:149-55. [PMID: 28839568 DOI: 10.1136/fg.2009.000935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
265 Singal P, Muniyappa R, Chisholm R, Hall G, Chen H, Quon MJ, Mather KJ. Simple modeling allows prediction of steady-state glucose disposal rate from early data in hyperinsulinemic glucose clamps. Am J Physiol Endocrinol Metab 2010;298:E229-36. [PMID: 19920219 DOI: 10.1152/ajpendo.00603.2009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
266 Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774-788. [PMID: 20683968 DOI: 10.1002/hep.23719] [Cited by in Crossref: 606] [Cited by in F6Publishing: 541] [Article Influence: 55.1] [Reference Citation Analysis]
267 Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obesity Reviews 2009;10:412-9. [DOI: 10.1111/j.1467-789x.2009.00594.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
268 Alisi A, Manco M, Devito R, Nobili V. Fatty Liver Disease. In: Freemark M, editor. Pediatric Obesity. New York: Springer; 2010. pp. 201-22. [DOI: 10.1007/978-1-60327-874-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
269 Kotronen A, Seppälä-Lindroos A, Bergholm R, Yki-Järvinen H. Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia. 2008;51:130-138. [PMID: 18008059 DOI: 10.1007/s00125-007-0867-x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 5.9] [Reference Citation Analysis]
270 Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-järvinen H. Gene expression in human NAFLD. American Journal of Physiology-Gastrointestinal and Liver Physiology 2008;294:G1281-7. [DOI: 10.1152/ajpgi.00074.2008] [Cited by in Crossref: 242] [Cited by in F6Publishing: 227] [Article Influence: 18.6] [Reference Citation Analysis]
271 Canavesi E, Porzio M, Ruscica M, Rametta R, Macchi C, Pelusi S, Fracanzani AL, Dongiovanni P, Fargion S, Magni P, Valenti L. Increased circulating adiponectin in males with chronic HCV hepatitis. Eur J Intern Med 2015;26:635-9. [PMID: 26293833 DOI: 10.1016/j.ejim.2015.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
272 Kamath S, Chavez AO, Gastaldelli A, Casiraghi F, Halff GA, Abrahamian GA, Davalli AM, Bastarrachea RA, Comuzzie AG, Guardado-Mendoza R, Jimenez-Ceja LM, Mattern V, Paez AM, Ricotti A, Tejero ME, Higgins PB, Rodriguez-Sanchez IP, Tripathy D, DeFronzo RA, Dick EJ Jr, Cline GW, Folli F. Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates. PLoS One 2011;6:e27617. [PMID: 22125617 DOI: 10.1371/journal.pone.0027617] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
273 Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 2019;1:312-28. [PMID: 32039382 DOI: 10.1016/j.jhepr.2019.07.002] [Cited by in Crossref: 81] [Cited by in F6Publishing: 50] [Article Influence: 40.5] [Reference Citation Analysis]
274 Lamprinou A, Willmann C, Machann J, Schick F, Eckstein SS, Dalla Man C, Visentin R, Birkenfeld AL, Peter A, Stefan N, Häring HU, Fritsche A, Heni M, Wagner R. Determinants of hepatic insulin clearance - Results from a Mendelian Randomization study. Metabolism 2021;119:154776. [PMID: 33862045 DOI: 10.1016/j.metabol.2021.154776] [Reference Citation Analysis]
275 Axelrod CL, Fealy CE, Mulya A, Kirwan JP. Exercise training remodels human skeletal muscle mitochondrial fission and fusion machinery towards a pro-elongation phenotype. Acta Physiol (Oxf) 2019;225:e13216. [PMID: 30408342 DOI: 10.1111/apha.13216] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
276 Chhimwal J, Patial V, Padwad Y. Beverages and Non-alcoholic fatty liver disease (NAFLD): Think before you drink. Clin Nutr 2021;40:2508-19. [PMID: 33932796 DOI: 10.1016/j.clnu.2021.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
277 Kim HY, Baik SJ, Lee HA, Lee BK, Lee HS, Kim TH, Yoo K. Relative fat mass at baseline and its early change may be a predictor of incident nonalcoholic fatty liver disease. Sci Rep 2020;10:17491. [PMID: 33060775 DOI: 10.1038/s41598-020-74659-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
278 Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care. 2006;9:637-642. [PMID: 16912563 DOI: 10.1097/01.mco.0000241677.40170.17] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 5.1] [Reference Citation Analysis]
279 Schindhelm RK, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ, Diamant M. Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med. 2007;24:430-435. [PMID: 17388959 DOI: 10.1111/j.1464-5491.2007.02100.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
280 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
281 Darcy J, Bartke A. From White to Brown - Adipose Tissue Is Critical to the Extended Lifespan and Healthspan of Growth Hormone Mutant Mice. Adv Exp Med Biol 2019;1178:207-25. [PMID: 31493229 DOI: 10.1007/978-3-030-25650-0_11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
282 Teppala S, Madhavan S, Shankar A. Bisphenol A and Metabolic Syndrome: Results from NHANES. Int J Endocrinol 2012;2012:598180. [PMID: 23251154 DOI: 10.1155/2012/598180] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
283 De Minicis S, Agostinelli L, Rychlicki C, Sorice GP, Saccomanno S, Candelaresi C, Giaccari A, Trozzi L, Pierantonelli I, Mingarelli E. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS One. 2014;9:e97136. [PMID: 24853141 DOI: 10.1371/journal.pone.0097136] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 7.3] [Reference Citation Analysis]
284 Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci (Lond) 2017;131:2701-4. [PMID: 29109303 DOI: 10.1042/CS20170987] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 11.8] [Reference Citation Analysis]
285 Rashidmayvan M, Mohammadshahi M, Seyedian SS, Haghighizadeh MH. The effect of Nigella sativa oil on serum levels of inflammatory markers, liver enzymes, lipid profile, insulin and fasting blood sugar in patients with non-alcoholic fatty liver. J Diabetes Metab Disord 2019;18:453-9. [PMID: 31890671 DOI: 10.1007/s40200-019-00439-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
286 Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol. 2014;36:115-132. [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
287 Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol. 2014;20:8351-8363. [PMID: 25024594 DOI: 10.3748/wjg.v20.i26.8351] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 49] [Article Influence: 10.5] [Reference Citation Analysis]
288 Kwak M, Kim D, Chung GE, Kim W, Kim YJ, Yoon J. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. Liver Int 2015;35:944-52. [DOI: 10.1111/liv.12552] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
289 Wang DQ, Portincasa P, Neuschwander-Tetri BA. Steatosis in the liver. Compr Physiol 2013;3:1493-532. [PMID: 24265237 DOI: 10.1002/cphy.c130001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
290 Wang XC, Zhan XR, Li XY, Yu JJ, Liu XM. MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:17914-17923. [PMID: 25548489 DOI: 10.3748/wjg.v20.i47.17914] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
291 Chang PF, Lin YC, Liu K, Yeh SJ, Ni YH. Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease. Int J Obes (Lond). 2015;39:1236-1240. [PMID: 25835554 DOI: 10.1038/ijo.2015.46] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
292 Whelan ME, Wright OR, Hickman IJ. A Review of the Effect of Dietary Composition on Fasting Substrate Oxidation in Healthy and Overweight Subjects. Crit Rev Food Sci Nutr 2016;56:146-51. [PMID: 25036818 DOI: 10.1080/10408398.2012.717975] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
293 Martinelli I, Micioni Di Bonaventura MV, Moruzzi M, Amantini C, Maggi F, Gabrielli MG, Fruganti A, Marchegiani A, Dini F, Marini C, Polidori C, Lupidi G, Amenta F, Tayebati SK, Cifani C, Tomassoni D. Effects of Prunus cerasus L. Seeds and Juice on Liver Steatosis in an Animal Model of Diet-Induced Obesity. Nutrients 2020;12:E1308. [PMID: 32375317 DOI: 10.3390/nu12051308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
294 Hong SH, Lee JS, Kim JA, Lee YB, Roh E, Hee Yu J, Kim NH, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi KM. Glycemic variability and the risk of nonalcoholic fatty liver disease : A nationwide population-based cohort study. Diabetes Res Clin Pract 2021;177:108922. [PMID: 34146602 DOI: 10.1016/j.diabres.2021.108922] [Reference Citation Analysis]
295 Mehmood A, Zhao L, Wang Y, Pan F, Hao S, Zhang H, Iftikhar A, Usman M. Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. Food Res Int 2021;142:110180. [PMID: 33773656 DOI: 10.1016/j.foodres.2021.110180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
296 Lu J, Fang B, Huang Y, Tao S, Sun B, Guan S, Jin Y. Epigallocatechin-3-gallate protects against 1,3-dichloro-2-propanol-induced lipid accumulation in C57BL/6J mice. Life Sciences 2018;209:324-31. [DOI: 10.1016/j.lfs.2018.08.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
297 Petta S, Gastaldelli A, Rebelos E, Bugianesi E, Messa P, Miele L, Svegliati-Baroni G, Valenti L, Bonino F. Pathophysiology of Non Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. [PMID: 27973438 DOI: 10.3390/ijms17122082] [Cited by in Crossref: 72] [Cited by in F6Publishing: 52] [Article Influence: 14.4] [Reference Citation Analysis]
298 Rhee EJ. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective. Endocrinol Metab (Seoul) 2019;34:226-33. [PMID: 31565874 DOI: 10.3803/EnM.2019.34.3.226] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 24.0] [Reference Citation Analysis]
299 Rebelos E, Iozzo P, Guzzardi MA, Brunetto MR, Bonino F. Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease. WJG 2021;27:4999-5018. [DOI: 10.3748/wjg.v27.i30.4999] [Reference Citation Analysis]
300 Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, Serviddio G, Federico A. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int J Mol Sci 2021;22:E436. [PMID: 33406763 DOI: 10.3390/ijms22010436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
301 Dongiovanni P, Valenti L. Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility? PPAR Res. 2013;2013:452061. [PMID: 23431284 DOI: 10.1155/2013/452061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
302 Savic D, Hodson L, Neubauer S, Pavlides M. The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E2178. [PMID: 32708036 DOI: 10.3390/nu12082178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
303 Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Biernacki D, Lo M, Suman A, Weber MH, Cusi K. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. Diabetes Care. 2016;39:632-638. [PMID: 26861926 DOI: 10.2337/dc15-1876] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 12.2] [Reference Citation Analysis]
304 Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis. 2007;11:75-104, ix. [PMID: 17544973 DOI: 10.1016/j.cld.2007.02.011] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 7.4] [Reference Citation Analysis]
305 Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep 2019;1:329-41. [PMID: 32039383 DOI: 10.1016/j.jhepr.2019.08.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
306 Liu Z, Hu Y, Yang X, Tan A, Gao Y, Qin X, Liang Y, Mo Z, Peng T. Combinative analysis of factors influence serum alanine aminotransferase activity in adult male population from southern China. Clin Biochem 2012;45:1683-8. [PMID: 22975640 DOI: 10.1016/j.clinbiochem.2012.08.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
307 Shigiyama F, Kumashiro N, Tsuneoka Y, Igarashi H, Yoshikawa F, Kakehi S, Funato H, Hirose T. Mechanisms of sleep deprivation-induced hepatic steatosis and insulin resistance in mice. American Journal of Physiology-Endocrinology and Metabolism 2018;315:E848-58. [DOI: 10.1152/ajpendo.00072.2018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
308 De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A, Svegliati-Baroni G. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014;59:1738-1749. [PMID: 23959503 DOI: 10.1002/hep.26695] [Cited by in Crossref: 175] [Cited by in F6Publishing: 156] [Article Influence: 25.0] [Reference Citation Analysis]
309 Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Jouness RI, Saponaro C. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology. 2016;63:107-116. [PMID: 26473614 DOI: 10.1002/hep.28287] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
310 Shigiyama F, Kumashiro N, Furukawa Y, Funayama T, Takeno K, Wakui N, Ikehara T, Nagai H, Taka H, Fujimura T, Uchino H, Tamura Y, Watada H, Nemoto T, Shiraga N, Sumino Y, Hirose T. Characteristics of hepatic insulin-sensitive nonalcoholic fatty liver disease. Hepatol Commun 2017;1:634-47. [PMID: 29404483 DOI: 10.1002/hep4.1077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
311 Kanwar P, Nelson JE, Yates K, Kleiner DE, Unalp-Arida A, Kowdley KV. Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol 2016;3:e000114. [PMID: 27933201 DOI: 10.1136/bmjgast-2016-000114] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
312 Yndestad A, Haukeland JW, Dahl TB, Halvorsen B, Aukrust P. Activin A in Nonalcoholic Fatty Liver Disease. Activins and Inhibins. Elsevier; 2011. pp. 323-42. [DOI: 10.1016/b978-0-12-385961-7.00015-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
313 Ferreira DM, Castro RE, Machado MV, Evangelista T, Silvestre A, Costa A, Coutinho J, Carepa F, Cortez-Pinto H, Rodrigues CM. Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. Diabetologia. 2011;54:1788-1798. [PMID: 21455726 DOI: 10.1007/s00125-011-2130-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
314 Liu Y, Liao L, Chen Y, Han F. Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells. Mol Med Rep 2019;19:4673-84. [PMID: 30957185 DOI: 10.3892/mmr.2019.10139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
315 Shi Y, Pizzini J, Wang H, Das F, Abdul Azees PA, Ghosh Choudhury G, Barnes JL, Zang M, Weintraub ST, Yeh CK, Katz MS, Kamat A. β2-Adrenergic receptor agonist induced hepatic steatosis in mice: modeling nonalcoholic fatty liver disease in hyperadrenergic states. Am J Physiol Endocrinol Metab 2021;321:E90-E104. [PMID: 34029162 DOI: 10.1152/ajpendo.00651.2020] [Reference Citation Analysis]
316 Bril F, McPhaul MJ, Kalavalapalli S, Lomonaco R, Barb D, Gray ME, Shiffman D, Rowland CM, Cusi K. Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. J Clin Endocrinol Metab 2021:dgab417. [PMID: 34190318 DOI: 10.1210/clinem/dgab417] [Reference Citation Analysis]
317 Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest 2020;130:1453-60. [PMID: 31805015 DOI: 10.1172/JCI134165] [Cited by in Crossref: 85] [Cited by in F6Publishing: 46] [Article Influence: 85.0] [Reference Citation Analysis]
318 Cox J, Williams S, Grove K, Lane RH, Aagaard-Tillery KM. A maternal high-fat diet is accompanied by alterations in the fetal primate metabolome. Am J Obstet Gynecol 2009;201:281.e1-9. [PMID: 19733280 DOI: 10.1016/j.ajog.2009.06.041] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
319 Xin J, Zeng D, Wang H, Ni X, Yi D, Pan K, Jing B. Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. Appl Microbiol Biotechnol 2014;98:6817-29. [PMID: 24811405 DOI: 10.1007/s00253-014-5752-1] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 9.4] [Reference Citation Analysis]
320 Ter Horst KW, Gilijamse PW, Versteeg RI, Ackermans MT, Nederveen AJ, la Fleur SE, Romijn JA, Nieuwdorp M, Zhang D, Samuel VT, Vatner DF, Petersen KF, Shulman GI, Serlie MJ. Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans. Cell Rep 2017;19:1997-2004. [PMID: 28591572 DOI: 10.1016/j.celrep.2017.05.035] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 25.7] [Reference Citation Analysis]
321 Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci 2018;75:3313-27. [PMID: 29936596 DOI: 10.1007/s00018-018-2860-6] [Cited by in Crossref: 234] [Cited by in F6Publishing: 194] [Article Influence: 78.0] [Reference Citation Analysis]
322 Fakhoury-Sayegh N, Trak-Smayra V, Khazzaka A, Esseily F, Obeid O, Lahoud-Zouein M, Younes H. Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets. Nutr Res Pract 2015;9:350-7. [PMID: 26244072 DOI: 10.4162/nrp.2015.9.4.350] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
323 Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr. 2015;4:101-108. [PMID: 26005676 DOI: 10.3978/j.issn.2304-3881.2015.01.03] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
324 Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med 2020;152:116-41. [PMID: 32156524 DOI: 10.1016/j.freeradbiomed.2020.02.025] [Cited by in Crossref: 90] [Cited by in F6Publishing: 70] [Article Influence: 90.0] [Reference Citation Analysis]
325 Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovasc Diabetol. 2012;11:61. [PMID: 22676459 DOI: 10.1186/1475-2840-11-61] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
326 Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20. [PMID: 28930295 DOI: 10.1038/nrgastro.2017.109] [Cited by in Crossref: 1421] [Cited by in F6Publishing: 1146] [Article Influence: 355.3] [Reference Citation Analysis]
327 Yang JS, Qi W, Farias-Pereira R, Choi S, Clark JM, Kim D, Park Y. Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte. Food Chem Toxicol 2019;125:595-604. [PMID: 30738135 DOI: 10.1016/j.fct.2019.02.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
328 Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2009;25:230-237. [PMID: 19396962 DOI: 10.1097/MOG.0b013e3283294a18] [Cited by in Crossref: 54] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
329 Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. Journal of Endocrinology 2013;218:R25-36. [DOI: 10.1530/joe-13-0201] [Cited by in Crossref: 155] [Cited by in F6Publishing: 72] [Article Influence: 19.4] [Reference Citation Analysis]
330 Mashek DG. Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr 2013;4:697-710. [PMID: 24228201 DOI: 10.3945/an.113.004648] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
331 Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod. 2010;25:212-220. [PMID: 19887498 DOI: 10.1093/humrep/dep380] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 6.8] [Reference Citation Analysis]
332 Enjoji M, Yasutake K, Kohjima M, Nakamuta M. Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. Int J Hepatol 2012;2012:925807. [PMID: 22550592 DOI: 10.1155/2012/925807] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
333 Hajighasem A, Farzanegi P, Mazaheri Z. Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease. Arch Physiol Biochem. 2018;1-8. [PMID: 29463133 DOI: 10.1080/13813455.2018.1441872] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
334 Li M, Zhang S, Wu Y, Ye J, Cao X, Liu J, Sun Y, Zhong B. Prevalence of Insulin Resistance in Subjects with Nonalcoholic Fatty Liver Disease and Its Predictors in a Chinese Population. Dig Dis Sci 2015;60:2170-6. [PMID: 25686742 DOI: 10.1007/s10620-015-3564-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
335 Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987-1000. [PMID: 16250043 DOI: 10.1002/hep.20920] [Cited by in Crossref: 512] [Cited by in F6Publishing: 426] [Article Influence: 32.0] [Reference Citation Analysis]
336 Guerra S, Gastaldelli A. The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes. Curr Opin Pharmacol 2020;55:165-74. [PMID: 33278735 DOI: 10.1016/j.coph.2020.10.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
337 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016;7:211-7. [PMID: 27190693 DOI: 10.4291/wjgp.v7.i2.211] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
338 VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL. High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol. 2009;175:355-364. [PMID: 19541928 DOI: 10.2353/ajpath.2009.080703] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
339 Adiels M, Westerbacka J, Soro-Paavonen A, Häkkinen AM, Vehkavaara S, Caslake MJ, Packard C, Olofsson SO, Yki-Järvinen H, Taskinen MR, Borén J. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007;50:2356-65. [PMID: 17849096 DOI: 10.1007/s00125-007-0790-1] [Cited by in Crossref: 120] [Cited by in F6Publishing: 108] [Article Influence: 8.6] [Reference Citation Analysis]
340 Vittal A, Shapses M, Sharma B, Sharma D, Sun Q, Sampson M, Lee W, Ben Yakov G, Rotman Y. Lipoprotein Insulin Resistance Index Reflects Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021;5:589-97. [PMID: 33860117 DOI: 10.1002/hep4.1658] [Reference Citation Analysis]
341 Lattuada G, Radaelli MG, De Cobelli F, Esposito A, Manzoni G, Perra S, Del Maschio A, Castoldi G, Perseghin G. Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver. Oxid Med Cell Longev 2019;2019:9796175. [PMID: 31097978 DOI: 10.1155/2019/9796175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
342 Luukkonen PK, Dufour S, Lyu K, Zhang XM, Hakkarainen A, Lehtimäki TE, Cline GW, Petersen KF, Shulman GI, Yki-Järvinen H. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2020;117:7347-54. [PMID: 32179679 DOI: 10.1073/pnas.1922344117] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 37.0] [Reference Citation Analysis]
343 Chen W, Balland E, Cowley MA. Hypothalamic Insulin Resistance in Obesity: Effects on Glucose Homeostasis. Neuroendocrinology 2017;104:364-81. [PMID: 28122381 DOI: 10.1159/000455865] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
344 Furukawa Y, Tamura Y, Takeno K, Funayama T, Kaga H, Suzuki R, Watanabe T, Kakehi S, Kanazawa A, Kawamori R, Watada H. Impaired peripheral insulin sensitivity in non-obese Japanese patients with type 2 diabetes mellitus and fatty liver. J Diabetes Investig 2017. [PMID: 28836350 DOI: 10.1111/jdi.12731] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
345 Hossain IA, Akter S, Rahman MK, Ali L. Gender Specific Association of Serum Leptin and Insulinemic Indices with Nonalcoholic Fatty Liver Disease in Prediabetic Subjects. PLoS One. 2015;10:e0142165. [PMID: 26569494 DOI: 10.1371/journal.pone.0142165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
346 Dong K, Zhao Q, Xue Y, Wei Y, Zhang Y, Yang Y. TCTP participates in hepatic metabolism by regulating gene expression involved in insulin resistance. Gene 2021;768:145263. [PMID: 33122078 DOI: 10.1016/j.gene.2020.145263] [Reference Citation Analysis]
347 Libby AE, Bales E, Orlicky DJ, McManaman JL. Perilipin-2 Deletion Impairs Hepatic Lipid Accumulation by Interfering with Sterol Regulatory Element-binding Protein (SREBP) Activation and Altering the Hepatic Lipidome. J Biol Chem. 2016;291:24231-24246. [PMID: 27679530 DOI: 10.1074/jbc.m116.759795] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 8.4] [Reference Citation Analysis]
348 Asai A, Chou PM, Bu HF, Wang X, Rao MS, Jiang A, DiDonato CJ, Tan XD. Dissociation of hepatic insulin resistance from susceptibility of nonalcoholic fatty liver disease induced by a high-fat and high-carbohydrate diet in mice. Am J Physiol Gastrointest Liver Physiol. 2014;306:G496-G504. [PMID: 24436353 DOI: 10.1152/ajpgi.00291.2013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
349 Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134:424-431. [PMID: 18242210 DOI: 0.1053/j.gastro.2007.11.038] [Reference Citation Analysis]
350 Rejeb J, Omezzine A, Boumaiza I, Rebhi L, Kaouthar K, Kalboussi N, Ben Rejeb N, Nabli N, Ben Abdelaziz A, Boughzala E, Bouslama A. Elevated Liver Enzymes in Metabolic Syndrome Are Associated with Coronary Stenosis in a Tunisian Population. Metabolic Syndrome and Related Disorders 2010;8:249-54. [DOI: 10.1089/met.2009.0077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
351 Fakhoury-sayegh N, Trak-smayra V, Sayegh R, Haidar F, Obeid O, Asmar S, Khazzaka A. Fructose threshold for inducing organ damage in a rat model of nonalcoholic fatty liver disease. Nutrition Research 2019;62:101-12. [DOI: 10.1016/j.nutres.2018.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
352 Cusi K. Nonalcoholic steatohepatitis in nonobese patients: Not so different after all. Hepatology. 2017;65:4-7. [PMID: 27650699 DOI: 10.1002/hep.28839] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
353 Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon. 2014;14:e23235. [PMID: 25598791 DOI: 10.5812/hepatmon.23235] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
354 Gianotti G, Cenni A, Bianchi G, Masetti M, Zappoli P, Muscari A, Zoli M. Diastolic dysfunction and cardiovascular risk in old subjects: possible association with NAFLD? Arch Gerontol Geriatr. 2014;58:188-195. [PMID: 24268461 DOI: 10.1016/j.archger.2013.10.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
355 Sangouni AA, Ghavamzadeh S. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. Diabetes Metab Syndr 2019;13:2917-22. [PMID: 31425956 DOI: 10.1016/j.dsx.2019.07.063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
356 Bae JC, Seo SH, Hur KY, Kim JH, Lee MS, Lee MK, Lee WY, Rhee EJ, Oh KW. Association between Serum Albumin, Insulin Resistance, and Incident Diabetes in Nondiabetic Subjects. Endocrinol Metab (Seoul). 2013;28:26-32. [PMID: 24396647 DOI: 10.3803/enm.2013.28.1.26] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
357 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
358 Macfarlane DP, Raubenheimer PJ, Preston T, Gray CD, Bastin ME, Marshall I, Iredale JP, Andrew R, Walker BR. Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver. Am J Physiol Gastrointest Liver Physiol 2014;307:G760-8. [PMID: 25104497 DOI: 10.1152/ajpgi.00030.2014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
359 Ogorodnikova AD, Khan UI, McGinn AP, Zeb I, Budoff MJ, Harman SM, Miller VM, Brinton EA, Manson JE, Hodis HN, Merriam GR, Cedars MI, Taylor HS, Naftolin F, Lobo RA, Santoro N, Wildman RP. Ectopic fat and adipokines in metabolically benign overweight/obese women: the Kronos Early Estrogen Prevention Study. Obesity (Silver Spring) 2013;21:1726-33. [PMID: 23670850 DOI: 10.1002/oby.20200] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
360 Kelly CT, Mansoor J, Dohm GL, Chapman WH 3rd, Pender JR 4th, Pories WJ. Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. Surgery 2014;156:405-11. [PMID: 24962189 DOI: 10.1016/j.surg.2014.04.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
361 Anty R, Lemoine M. Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S10-S20. [PMID: 21742296 DOI: 10.1016/s2210-7401(11)70003-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
362 Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018;98:2133-2223. [PMID: 30067154 DOI: 10.1152/physrev.00063.2017] [Cited by in Crossref: 475] [Cited by in F6Publishing: 368] [Article Influence: 237.5] [Reference Citation Analysis]
363 Arruda AP, Pers BM, Parlakgül G, Güney E, Inouye K, Hotamisligil GS. Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. Nat Med 2014;20:1427-35. [PMID: 25419710 DOI: 10.1038/nm.3735] [Cited by in Crossref: 335] [Cited by in F6Publishing: 287] [Article Influence: 47.9] [Reference Citation Analysis]
364 Rhee E, Lee W, Cho Y, Kim B, Sung K. Hyperinsulinemia and the Development of Nonalcoholic Fatty Liver Disease in Nondiabetic Adults. The American Journal of Medicine 2011;124:69-76. [DOI: 10.1016/j.amjmed.2010.08.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
365 Seo M, Inoue I, Tanaka M, Matsuda N, Nakano T, Awata T, Katayama S, Alpers DH, Komoda T. Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats. Dig Dis Sci. 2013;58:3534-3544. [PMID: 24166662 DOI: 10.1007/s10620-013-2879-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
366 Omelchenko E, Gavish D, Shargorodsky M. Adiponectin is better predictor of subclinical atherosclerosis than liver function tests in patients with nonalcoholic fatty liver disease. J Am Soc Hypertens 2014;8:376-80. [PMID: 24794207 DOI: 10.1016/j.jash.2014.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
367 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014. 00177] [Reference Citation Analysis]
368 Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134:424-431. [PMID: 18242210 DOI: 10.1053/j.gastro.2007.11.038] [Cited by in Crossref: 320] [Cited by in F6Publishing: 288] [Article Influence: 22.9] [Reference Citation Analysis]
369 Zhang SR, Fan XM. Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2015;21:3214-3222. [PMID: 25805927 DOI: 10.3748/wjg.v21.i11.3214] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
370 Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008;134:1369-1375. [PMID: 18355813 DOI: 10.1053/j.gastro.2008.01.075] [Cited by in Crossref: 357] [Cited by in F6Publishing: 327] [Article Influence: 27.5] [Reference Citation Analysis]
371 Petta S, Valenti L, Bugianesi E, Targher G, Bellentani S, Bonino F, Ferrannini E, Loguercio C, Lonardo A, Marra F, Mancini M, Miele L, Nobili V, Baroni GS, Alessandro F, Ballestri S, Rossana Brunetto M, Coco B, Grieco A, Fargion S, Kondili L, Nascimbeni F, Prinster A, Romagnoli D, Taddei S, Vanni E, Vella S. A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease 2016;48:333-42. [DOI: 10.1016/j.dld.2015.10.027] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
372 Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology 2020;158:1899-912. [PMID: 32061598 DOI: 10.1053/j.gastro.2019.12.054] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 34.0] [Reference Citation Analysis]
373 Rodrigues PM, Afonso MB, Simão AL, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM, Castro RE. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis 2017;8:e2748. [PMID: 28406477 DOI: 10.1038/cddis.2017.172] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
374 Jeanes YM, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev 2017;30:97-105. [PMID: 28222828 DOI: 10.1017/S0954422416000287] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]